Clinical trialNCT02521285Active, not recruitingPhase 2Interventional

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

SponsorNational Cancer Institute (NCI)Enrollment21Barrett EsophagusEsophageal Adenocarcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This randomized phase II trial studies the safety of and how well aspirin works in preventing Barrett's esophagus from returning after it has been successfully eliminated by radiofrequency ablation. Studying samples of tissue from patients with Barrett's esophagus for the levels of a specific protein that is linked to developing Barrett's esophagus may help doctors learn whether aspirin can prevent it from returning after it has been successfully treated.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert S Bresalier
M.D. Anderson Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Saint Michael'S Hospital
Toronto, Ontario, Canada

United States

Ucla / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Uchealth University of Colorado Hospital
Aurora, Colorado, United States
Northwestern University
Chicago, Illinois, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Kansas City Veterans Affairs Medical Center
Kansas City, Missouri, United States
Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
University of Pennsylvania/abramson Cancer Center
Philadelphia, Pennsylvania, United States
Baylor College of Medicine/dan L Duncan Comprehensive Cancer Center
Houston, Texas, United States
Ut Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Aspirin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Jan 2016
Primary completion: 18 Jun 2019
Completion: 30 Mar 2027
Last update posted: 17 Jun 2026
Registered enrollment: 21
Registry id: NCT02521285

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 30 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.